Abstract
Background: Inorganic nanoparticles (NPs) including those derived from metals (e.g., gold, silver), semiconductors (e.g., quantum dots), carbon dots, carbon nanotubes, or oxides (e.g., iron oxide), have been deeply investigated recently for diagnostic and therapeutic purposes in oncology. Compared to organic nanomaterials, inorganic NPs have several advantages and unique characteristics for better imaging and drug delivery. Still, only a limited number of inorganic NPs are translated into clinical practice.
Method: In this review, we discuss the progression of inorganic NPs for cancer therapy and imaging, focusing our attention on opportunities, limitations and challenges for the main constituting nanomaterials, including metallic and magnetic NPs. In particular, the pre-clinical and clinical trials from the bench toward the clinic are here investigated.
Results: Over the last few decades, the development of wide range of NPs with the ability to tune size, composition and functionality, has provided an excellent resource for nanomedicine. Inorganic NPs provide a great opportunity as drug carriers, due to the easy modification of targeting molecules, the control of drug release by different stimuli, and the effective delivery to target sites, thus resulting in having an improved therapeutic efficacy and in reducing side effects. Inorganic NPs are investigated in preclinical and clinical studies for the detection, diagnosis and treatment of many diseases. The stability of inorganic NPs offers a potential advantage over the traditional delivery methods. Inorganic NPs could enhance and improve current imaging and diagnostic techniques, such as MRI or PET. Even though, they have not yet been approved for drug delivery applications, their ability to respond to external stimuli is now widely investigated in clinic.
Conclusion: The successful translation of inorganic NPs to the clinic requires the development of a simple, safe, cost-effective, ecofriendly mode of synthesis, and a better understanding of the safety mechanisms, biodistribution and the pharmacokinetics of NPs. However, more attention should be given to concerns on long-term toxicity, carcinogenesis, immunogenicity, inflammation and tissue damage. Although, some inorganic NPs, which were apparently promising in the preclinical phase, were found not to be successful when translated to the clinic, several encouraging NPs are currently being developed for treatment and cancer care and for a wide variety of other diseases.
Keywords: Cancer therapy, clinical trials, diagnostic, inorganic nanoparticles, magnetic nanoparticles, metallic nanoparticles, nanotechnology, theranostics.
Current Medicinal Chemistry
Title:Inorganic Nanoparticles for Cancer Therapy: A Transition from Lab to Clinic
Volume: 25 Issue: 34
Author(s): Samer Bayda, Mohamad Hadla, Stefano Palazzolo, Pietro Riello, Giuseppe Corona, Giuseppe Toffoli and Flavio Rizzolio*
Affiliation:
- Experimental and Clinical Pharmacology, Department of Translational Research, National Cancer Institute and Center for Molecular Biomedicine - CRO, Aviano,Italy
Keywords: Cancer therapy, clinical trials, diagnostic, inorganic nanoparticles, magnetic nanoparticles, metallic nanoparticles, nanotechnology, theranostics.
Abstract: Background: Inorganic nanoparticles (NPs) including those derived from metals (e.g., gold, silver), semiconductors (e.g., quantum dots), carbon dots, carbon nanotubes, or oxides (e.g., iron oxide), have been deeply investigated recently for diagnostic and therapeutic purposes in oncology. Compared to organic nanomaterials, inorganic NPs have several advantages and unique characteristics for better imaging and drug delivery. Still, only a limited number of inorganic NPs are translated into clinical practice.
Method: In this review, we discuss the progression of inorganic NPs for cancer therapy and imaging, focusing our attention on opportunities, limitations and challenges for the main constituting nanomaterials, including metallic and magnetic NPs. In particular, the pre-clinical and clinical trials from the bench toward the clinic are here investigated.
Results: Over the last few decades, the development of wide range of NPs with the ability to tune size, composition and functionality, has provided an excellent resource for nanomedicine. Inorganic NPs provide a great opportunity as drug carriers, due to the easy modification of targeting molecules, the control of drug release by different stimuli, and the effective delivery to target sites, thus resulting in having an improved therapeutic efficacy and in reducing side effects. Inorganic NPs are investigated in preclinical and clinical studies for the detection, diagnosis and treatment of many diseases. The stability of inorganic NPs offers a potential advantage over the traditional delivery methods. Inorganic NPs could enhance and improve current imaging and diagnostic techniques, such as MRI or PET. Even though, they have not yet been approved for drug delivery applications, their ability to respond to external stimuli is now widely investigated in clinic.
Conclusion: The successful translation of inorganic NPs to the clinic requires the development of a simple, safe, cost-effective, ecofriendly mode of synthesis, and a better understanding of the safety mechanisms, biodistribution and the pharmacokinetics of NPs. However, more attention should be given to concerns on long-term toxicity, carcinogenesis, immunogenicity, inflammation and tissue damage. Although, some inorganic NPs, which were apparently promising in the preclinical phase, were found not to be successful when translated to the clinic, several encouraging NPs are currently being developed for treatment and cancer care and for a wide variety of other diseases.
Export Options
About this article
Cite this article as:
Bayda Samer, Hadla Mohamad, Palazzolo Stefano, Riello Pietro, Corona Giuseppe, Toffoli Giuseppe and Rizzolio Flavio*, Inorganic Nanoparticles for Cancer Therapy: A Transition from Lab to Clinic, Current Medicinal Chemistry 2018; 25 (34) . https://dx.doi.org/10.2174/0929867325666171229141156
DOI https://dx.doi.org/10.2174/0929867325666171229141156 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Practical Aspects in the Use of Biomarkers for the Development of Cancer Vaccines
Current Cancer Therapy Reviews Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Evaluation of Cytotoxic Mechanisms of Clinacanthus Nutans Extracts in Cancer Cells
The Natural Products Journal Overview of Naphthalimide Analogs as Anticancer Agents
Current Medicinal Chemistry Distribution of Chloroaluminum Phthalocyanine in a Lipid Nano-Emulsion as Studied by Second-Derivative Spectrophotometry
Micro and Nanosystems Lung Cancer Stem Cells as a Target for Therapy
Anti-Cancer Agents in Medicinal Chemistry A Systematic Review of Selected Musculoskeletal Late Effects in Survivors of Childhood Cancer
Current Pediatric Reviews Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets Alternative Strategies for the Derivation of Human Embryonic Stem Cell Lines and the Role of Dead Embryos
Current Stem Cell Research & Therapy Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Modulation of Expression and Activity of ABC Transporters by the Phytoestrogen Genistein. Impact on Drug Disposition
Current Medicinal Chemistry Current Understanding of Interactions between Nanoparticles and ABC Transporters in Cancer Cells
Current Medicinal Chemistry Signaling Pathways of the ING Proteins in Apoptosis
Current Drug Targets Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay
Current Medical Imaging Mediterranean Diet and Oxidation: Nuts and Olive Oil as Important Sources of Fat and Antioxidants
Current Topics in Medicinal Chemistry Role of Human and Mouse HspB1 in Metastasis
Current Molecular Medicine Genotyping as a Tool to Predict Adverse Drug Reactions
Current Topics in Medicinal Chemistry Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design Synthetic Lethality-Based Therapeutics: Perspectives for Applications in Colorectal Cancer
Current Cancer Drug Targets